Experimental drug shows promise in treatment of NAFLD in phase 2 trial
USA: An experimental, oral, once-daily, selective fatty acid synthase (FASN) inhibitor has shown promise for the treatment of non-alcoholic steatohepatitis (NASH), an aggressive form of nonalcoholic fatty liver disease (NAFLD), show findings from FASCINATE-1 Phase 2a clinical trial.
The findings of the trial are published in Gastroenterology, the official journal of the American Gastroenterological Association
According to the study, administration of TVB-2640 in patients with non-alcoholic steatohepatitis significantly improved inflammation, steatosis, fibrosis, lipotoxicity, and metabolic biomarkers only after 12-weeks of the treatment.
George Kemble, chief executive officer of Sagimet Biosciences Inc, said, "The results from our FASCINATE-1 Phase 2a trial published in this prestigious peer-reviewed journal are very encouraging. The significant improvement across steatosis, inflammation, lipotoxicity, fibrosis, and metabolic biomarkers after only 12 weeks of TVB-2640 treatment bring hope that we are getting closer to a potential therapy for patients with NASH."
Reference:
The study titled, "TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial," is published in the journal Gastroenterology.
https://www.gastrojournal.org/article/S0016-5085(21)03276-5/fulltext
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.